After a $200M financing, Highland Therapeutics falls silent on ADHD drug’s fate as PDUFA sails by
Back at the beginning of this year, the folks at Toronto-based Highland Therapeutics celebrated a $200 million financing completed through Morgan Stanley. That cash, they said, would go to commercializing their ADHD drug HLD200 through their wholly owned subsidiary Ironshore, touting a drug they have frequently heralded as a breakthrough in the field as it faced a July 30 PDUFA date. They even hired some Shire vets to help grab market share.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.